Trillium Therapeutics Company Profile (NASDAQ:TRIL)

About Trillium Therapeutics (NASDAQ:TRIL)

Trillium Therapeutics logoTrillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $64.76 million
  • Outstanding Shares: 10,794,000
Average Prices:
  • 50 Day Moving Avg: $5.08
  • 200 Day Moving Avg: $5.15
  • 52 Week Range: $4.15 - $15.87
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.15
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.74 per share
  • Price / Book: 3.91
  • EBITDA: ($28,620,000.00)
  • Return on Equity: -178.08%
  • Return on Assets: -61.40%
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 7.92%
  • Quick Ratio: 7.92%
  • Average Volume: 51,400 shs.
  • Beta: 1.29
  • Short Ratio: 20.39

Frequently Asked Questions for Trillium Therapeutics (NASDAQ:TRIL)

What is Trillium Therapeutics' stock symbol?

Trillium Therapeutics trades on the NASDAQ under the ticker symbol "TRIL."

When will Trillium Therapeutics make its next earnings announcement?

Trillium Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November, 9th 2017. View Earnings Estimates for Trillium Therapeutics.

Where is Trillium Therapeutics' stock going? Where will Trillium Therapeutics' stock price be in 2017?

5 brokerages have issued twelve-month price objectives for Trillium Therapeutics' shares. Their forecasts range from $7.00 to $20.00. On average, they expect Trillium Therapeutics' stock price to reach $15.00 in the next twelve months. View Analyst Ratings for Trillium Therapeutics.

What are analysts saying about Trillium Therapeutics stock?

Here are some recent quotes from research analysts about Trillium Therapeutics stock:

  • 1. According to Zacks Investment Research, "Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company's lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (do not eat) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (eat) signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. " (10/17/2017)
  • 2. Cowen and Company analysts commented, "The key investor concern coming into ASH was safety of the 0.2mg/kg/week dose of." (12/5/2016)

Who are some of Trillium Therapeutics' key competitors?

How do I buy Trillium Therapeutics stock?

Shares of Trillium Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Trillium Therapeutics' stock price today?

One share of Trillium Therapeutics stock can currently be purchased for approximately $6.80.

MarketBeat Community Rating for Trillium Therapeutics (NASDAQ TRIL)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  125 (Vote Outperform)
Underperform Votes:  63 (Vote Underperform)
Total Votes:  188
MarketBeat's community ratings are surveys of what our community members think about Trillium Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Trillium Therapeutics (NASDAQ:TRIL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $15.00 (120.59% upside)
Consensus Price Target History for Trillium Therapeutics (NASDAQ:TRIL)
Price Target History for Trillium Therapeutics (NASDAQ:TRIL)
Analysts' Ratings History for Trillium Therapeutics (NASDAQ:TRIL)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/14/2017HC WainwrightSet Price TargetBuy$7.00MediumView Rating Details
7/5/2017Cowen and CompanyReiterated RatingBuyMediumView Rating Details
6/9/2017Ladenburg Thalmann Financial ServicesReiterated RatingBuy$18.00LowView Rating Details
11/4/2016Bloom BurtonReiterated RatingBuyN/AView Rating Details
11/3/2016Leerink SwannReiterated RatingOutperform$20.00N/AView Rating Details
10/6/2016BTIG ResearchInitiated CoverageBuy$21.00N/AView Rating Details
6/6/2016Oppenheimer Holdings, Inc.Reiterated RatingBuy$38.00N/AView Rating Details
(Data available from 10/18/2015 forward)


Earnings History for Trillium Therapeutics (NASDAQ:TRIL)
No earnings announcements for this company have been tracked by


Earnings Estimates for Trillium Therapeutics (NASDAQ:TRIL)
2017 EPS Consensus Estimate: ($2.98)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.80)($0.80)($0.80)
Q2 20171($0.83)($0.83)($0.83)
Q3 20171($0.83)($0.83)($0.83)
Q4 20171($0.52)($0.52)($0.52)
(Data provided by Zacks Investment Research)


Dividend History for Trillium Therapeutics (NASDAQ:TRIL)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Trillium Therapeutics (NASDAQ:TRIL)
No insider trades for this company have been tracked by


Headline Trends for Trillium Therapeutics (NASDAQ:TRIL)
Latest Headlines for Trillium Therapeutics (NASDAQ:TRIL)
DateHeadline logo Brokerages Expect Trillium Therapeutics Inc. (TRIL) to Announce -$0.86 EPS - October 16 at 6:26 PM logoTrillium Therapeutics (TRIL) & Its Competitors Head to Head Comparison - October 16 at 2:08 PM logoTrillium Therapeutics' TTI-621 Program Featured at the EORTC CLTF Cutaneous Lymphoma Conference - October 16 at 7:20 AM logoTrillium Therapeutics (TRIL) & The Competition Financial Survey - October 12 at 12:28 AM logoTrillium Therapeutics Inc. (TRIL) Given Average Rating of "Buy" by Brokerages - October 11 at 6:28 AM logoContrasting Trillium Therapeutics (TRIL) & Its Peers - October 10 at 2:16 PM logoTrillium Therapeutics (TRIL) & The Competition Critical Contrast - October 10 at 2:14 PM logoAnalyzing Trillium Therapeutics (TRIL) and Its Rivals - October 6 at 6:26 AM logoAnalyzing Trillium Therapeutics (TRIL) & Mirati Therapeutics (MRTX) - October 4 at 12:22 AM logo-$0.86 Earnings Per Share Expected for Trillium Therapeutics Inc. (TRIL) This Quarter - September 28 at 2:06 AM logoTrillium Therapeutics Inc. (TRIL) Receives Consensus Rating of "Buy" from Analysts - September 16 at 6:36 AM logoReviewing Affymax (AFFY) and Trillium Therapeutics (TRIL) - September 12 at 8:32 AM logoTrillium Therapeutics (TRIL) & XOMA Corporation (XOMA) Critical Contrast - September 8 at 8:29 PM logoTrillium Therapeutics Inc. (TRIL) Given Consensus Rating of "Buy" by Brokerages - August 22 at 6:44 AM logoHC Wainwright Analysts Give Trillium Therapeutics Inc. (TRIL) a $7.00 Price Target - August 14 at 11:40 AM logoHead-To-Head Contrast: Trillium Therapeutics (NASDAQ:TRIL) & Mateon Therapeutics (MATN) - August 12 at 12:12 PM logoTrillium Therapeutics Inc. (NASDAQ:TRIL) Expected to Announce Earnings of -$0.95 Per Share - August 3 at 12:12 PM logoTrillium Therapeutics Inc. (TRIL) Receives Average Recommendation of "Buy" from Analysts - July 28 at 7:41 AM logo Brokerages Anticipate Trillium Therapeutics Inc. (NASDAQ:TRIL) to Post -$1.02 Earnings Per Share - July 12 at 7:34 AM logoCowen and Company Reaffirms Buy Rating for Trillium Therapeutics Inc. (TRIL) - July 9 at 6:02 PM logoTrillium Provides Update on Small Molecule Programs - July 6 at 2:09 PM logoTrillium Therapeutics Inc. (TRIL) Given Average Rating of "Buy" by Analysts - July 3 at 8:34 AM logoBRIEF-Trillium Therapeutics presents TTI-621 preclinical data at AACR annual meeting - April 4 at 1:11 AM logoTrillium Therapeutics (TRIL) Highlights TTI-621 Preclinical Data at ... - - April 3 at 8:09 PM logoTrillium Therapeutics (TRIL) Outlines 2017 Anticipated Activities and Milestones - February 3 at 6:19 AM logoBRIEF-Trillium Therapeutics Inc intends to provide an update on ongoing TTI-621 trials - February 3 at 6:19 AM logoBRIEF-Trillium Therapeutics doses first patient with TTI-621 in phase 1 solid tumor trial - February 1 at 7:00 AM logoTrillium Therapeutics (TRIL) Initiates Dosing in Second Phase 1 Trial of TTI-621 - February 1 at 7:00 AM logoTrillium Therapeutics (TRIL) Announces Presentation of Initial TTI-621 Data in AMMs - December 5 at 8:37 AM logo1:46 am Trillium Therapeutics presents initial data from ongoing study of TTI-621; believes data from this study provide preliminary evidence that TTI-621 monotherapy is both active and well tolerated - December 5 at 8:37 AM



Trillium Therapeutics (TRIL) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.